To recover your password please fill in your email address
Please fill in below form to create an account with us
A randomised phase 2 trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer (ANZUP1603).
See ANZCTR for full trial details >
|
Trial Summary: |
To determine the activity and safety of Lu-PSMA vs cabazitaxel in patients with castration resistant prostate cancer. |
|
Supported By: |
Prostate Cancer Foundation Australia (PCFA), Endocyte, Australian Nuclear Science and Technology Organisation (ANSTO) |
|
Eligibility: |
Men with castration resistant prostate cancer suitable for chemotherapy with cabazitaxel (surgical or medical castration, and previous chemotherapy with docetaxel). |
|
Registration ID: |
ACTRN12617001590358 |
|
Participation: |
Australia |
|
Australian Lead Group: |
ANZUP |
|
Status: |
Completed |
|
Activation Date: |
29/01/2018 |
|
Chairs: |
Prof Michael Hofman |
|
Contact: |